LLY

Eli Lilly & Co
D

LLY

Arincen80/100B

Eli Lilly & Co return on equity (ROE)

Eli Lilly & Co's return on equity is 68.49%: net income of 27.58B USD over the last twelve months on shareholders' equity of 40.27B USD.

Today
68.49%
Average, 5 years
64.03%
Low, 5 years
44.46%
High, 5 years
81.02%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 27.58B ÷ 40.27B = 68.49%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

Why is Eli Lilly & Co's return on equity so high?

Net margin
31.7%
profit on each dollar of sales
Asset turnover
0.58×
sales on each dollar of assets
Equity multiplier
4.24×
assets on each dollar of equity
Return on equity
77.8%
FY2025
  • FY202531.7% × 0.58 × 4.24 = 77.8%
  • FY202423.5% × 0.57 × 5.55 = 74.6%
  • FY202315.4% × 0.53 × 5.94 = 48.6%
  • FY202221.9% × 0.58 × 4.65 = 58.6%
  • FY202119.7% × 0.58 × 5.44 = 62.2%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)Net incomeShareholders' equity
Today68.49%27.58B40.27B
FY202531 Dec 202577.78%20.64B26.54B
FY202431 Dec 202474.62%10.59B14.19B
FY202331 Dec 202348.65%5.24B10.77B
FY202231 Dec 202258.64%6.24B10.65B
FY202131 Dec 202162.16%5.58B8.98B
FY202031 Dec 2020109.79%6.19B5.64B
FY201931 Dec 2019319.09%8.32B2.61B
FY201831 Dec 201832.88%3.23B9.83B
FY201731 Dec 2017-1.76%-204.10M11.59B
FY201631 Dec 201619.54%2.74B14.01B
FY201531 Dec 201516.53%2.41B14.57B
FY201431 Dec 201415.55%2.39B15.37B
FY201331 Dec 201326.57%4.68B17.63B
FY201231 Dec 201227.69%4.09B14.77B
FY201131 Dec 201132.11%4.35B13.54B
FY201031 Dec 201040.82%5.07B12.42B
FY200931 Dec 200945.45%4.33B9.52B
FY200831 Dec 2008-30.76%-2.07B6.74B
FY200731 Dec 200721.87%2.95B13.50B
FY200631 Dec 200624.25%2.66B10.98B
FY200531 Dec 200518.34%1.98B10.79B
FY200431 Dec 200416.58%1.81B10.92B
FY200331 Dec 200326.22%2.56B9.76B
FY200231 Dec 200232.73%2.71B8.27B
FY200131 Dec 200139.13%2.78B7.10B
FY200031 Dec 200050.57%3.06B6.05B
FY199931 Dec 199954.28%2.72B5.01B
FY199831 Dec 199847.52%2.11B4.43B
FY199731 Dec 1997-8.29%-385.10M4.65B
FY199631 Dec 199624.98%1.52B6.10B
FY199531 Dec 199542.17%2.29B5.43B
FY199431 Dec 199424.01%1.29B5.36B
FY199331 Dec 199310.75%491.10M4.57B
FY199231 Dec 199216.92%827.60M4.89B
FY199131 Dec 199126.47%1.31B4.97B
FY199031 Dec 199032.51%1.13B3.47B
FY198931 Dec 198925.01%939.50M3.76B
FY198831 Dec 198823.59%761.00M3.23B
FY198731 Dec 198721.16%643.70M3.04B
FY198631 Dec 198620.38%558.20M2.74B
FY198531 Dec 198521.68%517.60M2.39B

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,Debt to equity,Current ratio,All ratios

Common questions about Eli Lilly & Co's ROE

Source: Financial Modeling Prep